AUTHOR=Bagchus Wilhelmina , Yalkinoglu Özkan , Wolna Peter 

TITLE=Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris®) in Pituitary-Suppressed Healthy Women

JOURNAL=Frontiers in Endocrinology

VOLUME=8

YEAR=2018

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2017.00371

DOI=10.3389/fendo.2017.00371

ISSN=1664-2392

ABSTRACT=<p>This was a Phase I, open-label, randomized, two-period, two-sequence crossover study [<uri xlink:href="http://ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</uri> NCT02317809 (<uri xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02317809" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.clinicaltrials.gov/ct2/show/NCT02317809</uri>); EudraCT 2014-003506-32] assessing the bioequivalence of the liquid and freeze-dried formulations of fixed-dose, fixed-ratio (2:1) combination recombinant human follicle-stimulating hormone plus recombinant human luteinizing hormone (r-hFSH/r-hLH). The safety and tolerability of the two formulations were also assessed. Healthy premenopausal women were randomized to one of two crossover dosing schedules. Subjects in Treatment Sequence 1 received a single subcutaneous dose (900/450 IU r-hFSH/r-hLH) of the liquid formulation of r-hFSH/r-hLH on Day 1 of Dose Period 1 and, after a washout period of at least 14 days, a single subcutaneous dose (900/450 IU r-hFSH/r-hLH) of the freeze-dried formulation of r-hFSH/r-hLH (reconstituted in water for injection prior to administration) on Day 1 of Dose Period 2. Subjects in Treatment Sequence 2 received the treatments in reverse order. The primary endpoints were AUC<sub>0–</sub><italic><sub><bold>t</bold></sub></italic> (area under the serum concentration–time curve from time 0 to the time of the last quantifiable concentration) and <italic>C</italic><sub>max</sub> (maximum serum concentration) for FSH and LH, both baseline corrected. A total of 34 subjects were randomized, and 22 subjects were included in the bioequivalence evaluation. Overall, the mean observed PK profiles and individual PK parameters were comparable for the liquid and freeze-dried formulations, although a median difference in the <italic>t</italic><sub>max</sub> (time to reach maximum observed concentration) of FSH of ~4.5 h was observed between the formulations. The calculated 90% confidence intervals of the mean liquid formulation/freeze-dried formulation ratios for <italic>C</italic><sub>max</sub> and AUC<sub>0–</sub><italic><sub><bold>t</bold></sub></italic> were within the bioequivalence range (80–125%) for both LH and FSH, confirming bioequivalence between the two formulations. The safety and tolerability profiles of the two formulations were similar. The liquid formulation can, therefore, be expected to provide the same efficacy as the freeze-dried formulation, with no differences in tolerability.</p>